[go: up one dir, main page]

Chen et al., 2020 - Google Patents

Stability, reduction, and cytotoxicity of platinum (IV) anticancer prodrugs bearing carbamate axial ligands: comparison with their carboxylate analogues

Chen et al., 2020

Document ID
2605699030736309459
Author
Chen S
Yao H
Zhou Q
Tse M
Gunawan Y
Zhu G
Publication year
Publication venue
Inorganic Chemistry

External Links

Snippet

Platinum (IV) complexes containing carboxylate and carbamate ligands at the axial position have been reported previously. A better understanding of the similarity and difference between the two types of ligands will provide us with new insights and more choices to …
Continue reading at pubs.acs.org (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48007—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the pharmacologically- or therapeutically-active agent being covalently bound or complexed to a modifying agent
    • A61K47/48023—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the pharmacologically- or therapeutically-active agent being covalently bound or complexed to a modifying agent the modifying agent being an organic compound
    • A61K47/48061—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the pharmacologically- or therapeutically-active agent being covalently bound or complexed to a modifying agent the modifying agent being an organic compound the modifying agent being a heterocyclic compound
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic System
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic System compounds of the platinum group
    • C07F15/0086—Platinum compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with heteroatoms or with carbon atoms having three bonds to hetero atoms, with at the most one to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48169—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being an organic macromolecular compound, i.e. an oligomeric, polymeric, dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals

Similar Documents

Publication Publication Date Title
Chen et al. Stability, reduction, and cytotoxicity of platinum (IV) anticancer prodrugs bearing carbamate axial ligands: comparison with their carboxylate analogues
Ma et al. Glycosylated platinum (IV) complexes as substrates for glucose transporters (GLUTs) and organic cation transporters (OCTs) exhibited cancer targeting and human serum albumin binding properties for drug delivery
Andres et al. Synthesis, characterization, and biological activity of hybrid thiosemicarbazone–alkylthiocarbamate metal complexes
King et al. Bis (thiosemicarbazone) complexes of cobalt (III). Synthesis, characterization, and anticancer potential
Velders et al. Strong differences in the in vitro cytotoxicity of three isomeric dichlorobis (2-phenylazopyridine) ruthenium (II) complexes
Lenis-Rojas et al. RuII (p-cymene) compounds as effective and selective anticancer candidates with no toxicity in vivo
Haribabu et al. Water-soluble mono-and binuclear Ru (η6-p-cymene) complexes containing indole thiosemicarbazones: Synthesis, DFT modeling, biomolecular interactions, and in vitro anticancer activity through apoptosis
Clavel et al. Modulating the anticancer activity of ruthenium (II)–arene complexes
Sivaram et al. Syntheses, characterizations, and a preliminary comparative cytotoxicity study of gold (I) and gold (III) complexes bearing benzimidazole-and pyrazole-derived N-heterocyclic carbenes
Summa et al. Thermodynamic and kinetic studies on reactions of Pt (II) complexes with biologically relevant nucleophiles
Zheng et al. Pt (IV) prodrugs designed to bind non-covalently to human serum albumin for drug delivery
Sinisi et al. Dependence of the reduction products of platinum (IV) prodrugs upon the configuration of the substrate, bulk of the carrier ligands, and nature of the reducing agent
Ang et al. Synthesis and characterization of platinum (IV) anticancer drugs with functionalized aromatic carboxylate ligands: influence of the ligands on drug efficacies and uptake
Chen et al. Influence of equatorial and axial carboxylato ligands on the kinetic inertness of platinum (IV) complexes in the presence of ascorbate and cysteine and within DLD-1 cancer cells
Nazarov et al. Anthracene-tethered ruthenium (II) arene complexes as tools to visualize the cellular localization of putative organometallic anticancer compounds
Komeda et al. New isomeric azine-bridged dinuclear platinum (II) complexes circumvent cross-resistance to cisplatin
Qi et al. Developing an anticancer copper (II) pro-drug based on the His242 residue of the human serum albumin carrier IIA subdomain
Swaminathan et al. Coordination behavior of acylthiourea ligands in their Ru (II)–benzene complexes─ structures and anticancer activity
Hotze et al. Synthesis, characterization, and crystal structure of α-[Ru (azpy) 2 (NO3) 2](azpy= 2-(Phenylazo) pyridine) and the products of its reactions with guanine derivatives
Gou et al. Developing anticancer copper (II) pro-drugs based on the nature of cancer cells and the human serum albumin carrier IIA subdomain
Intini et al. Novel antitumor platinum (II) conjugates containing the nonsteroidal anti-inflammatory agent diclofenac: synthesis and dual mechanisms of antiproliferative effects
Ruiz et al. Synthesis and antiproliferative activity of a C, N-cycloplatinated (II) complex with a potentially intercalative anthraquinone pendant
Messori et al. Reactivity and biological properties of a series of cytotoxic PtI2 (amine) 2 complexes, either cis or trans configured
Budzisz et al. Synthesis, cytotoxic effect, and structure− activity relationship of Pd (II) complexes with coumarin derivatives
Liu et al. Study on antitumor platinum (II) complexes of chiral diamines with dicyclic species as steric hindrance